• Users Online: 94479
  • Home
  • Print this page
  • Email this page
SYMPOSIUM
Year : 2007  |  Volume : 55  |  Issue : 6  |  Page : 427-430

Pegaptanib sodium for ocular vascular disease


1 Retina-Vitreous Service, Aravind Eye Hospital and Postgraduate Institute, Anna Nagar, Madurai, India
2 Chairman, Aravind Eye Care System, Anna Nagar, Madurai, India
3 OSI Eyetech, Inc., New York, USA
4 Director, The Uveitis Service, California Pacific Medical Center, San Francisco, California and Adjunct Clinical Professor, Department of Ophthalmology, Stanford University School of Medicine, Stanford, California, USA

Correspondence Address:
Emmett T Cunningham Jr
801 Gateway Boulevard, Suite 410, South San Francisco, California 94080
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0301-4738.36476

Rights and Permissions

Pegaptanib sodium (Macugen™) is a selective RNA aptamer that inhibits vascular endothelial growth factor (VEGF) 165 , the VEGF isoform primarily responsible for pathologic ocular neovascularization and vascular permeability, while sparing the physiological isoform VEGF 121 . After more than 10 years in development and preclinical study, pegaptanib was shown in clinical trials to be effective in treating choroidal neovascularization associated with age-related macular degeneration. Its excellent ocular and systemic safety profile has also been confirmed in patients receiving up to three years of therapy. Early, well-controlled studies further suggest that pegaptanib may provide therapeutic benefit for patients with diabetic macular edema, proliferative diabetic retinopathy and retinal vein occlusion. Notably, pegaptanib was the first available aptamer approved for therapeutic use in humans and the first VEGF inhibitor available for the treatment of ocular vascular diseases.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed5421    
    Printed140    
    Emailed4    
    PDF Downloaded900    
    Comments [Add]    
    Cited by others 19    

Recommend this journal